Models in Parkinson’s research: are we addressing the right questions? by Fricker, RA
Author Manuscript: Fricker, R. (2011) Models in Parkinson’s research: are we addressing the right questions, from Advances in 
Clinical Neuroscience and Rehabilitation, 11(4), September/October, pp.35 available from http://www.acnr.co.uk/archive.htm ©Whitehouse Publishing 
 
Conference Reports 
Models in Parkinson’s Research: Are we addressing the right questions? 
Conference details: 18 May 2011; London, UK. Reviewed by: Dr Rosemary Fricker, Senior 
Lecturer, Keele University, UK. 
 
The seventh Research Conference of the UK Special Parkinson’s Research Interest Group 
(SPRING) brought together leading scientists and clinicians from across the globe to debate 
the value of current models of Parkinson’s disease (PD). The aim of this one day meeting 
was to discuss the usefulness of current PD models in broadening our understanding of the 
disease process, and as a tool to test future therapies. 
 
The first session set the scene by identifying the key features of PD that need to be 
reproduced in models. Jose Obeso (Navarra Medical School, Spain) and Tamas Revesz (UCL, 
London) described the complexity of neurodegeneration in PD, which affects many neuron 
subtypes and not solely the nigrostriatal dopamine neurons, causing a long phase of 
preclinical pathology, and evolving not only the cardinal motor symptoms but also cognitive 
impairments and dementia seen in PD. In addition, neuronal pathology appears as Lewy 
neurites in neuronal processes as well as Lewy bodies within cells, suggesting that problems 
with neurotransmission may be a key component of the disease process. There was some 
disagreement as to whether PD pathology is synchronized and multisystemic, or if it 
spreads in a caudo-rostral fashion from one region to another (the Braak hypothesis). 
 
However, both speakers concluded that an ideal animal model should incorporate: age 
dependent and focal loss of dopamine neurons with associated motor dysfunction; Lewy 
body and Lewy neurite pathology; and progressive neurodegeneration that represents 
the non-motor components of the disease. The second session focussed more specifically 
on rodent models of PD.  
 
Tim Greenamyre (Pittsburgh University, USA) gave an eloquent overview of the rotenone 
model developed in his laboratory, highlighting the strengths of this toxin-induced neuron 
degeneration. Rotenone targets complex 1 in the mitochondria, inhibiting mitochondrial 
respiration and thus energy metabolism. 
 
Greenamyre’s group have observed iron deposition in the Substantia nigra pars compacta 
(SNc) following rotenone administration, suggesting that iron may contribute to the 
pathology of the disease. Peter Magill (Oxford University) reported work to elucidate the 
nature of neuronal firing patterns in the basal ganglia circuitry, and how these are affected 
in PD to cause an increase in bradykinesia and rigidity. Injecting 6-hydroxydopamine to the 
basal ganglia (the 6-OHDA rat model) causes large changes in the β oscillation firing patterns 
of basal ganglia neurons, with increased synchrony of pairs of neurons particularly within 
the Globus Pallidus (GP).A single GP neuron can innervate neurons in the GP, 
Entopeduncular nucleus, Subthalamic nucleus and Substantia nigra pars reticulata. Thus, 
death of SNc dopaminergic neurons may cause whole networks of neurons to undergo 
changes in rhythm, oscillation and synchrony and, by firing at the wrong time or in the 
wrong place within the basal ganglia, causing many of the symptoms of PD. 
Dysfunction of the proteasome in clearing unwanted proteins from neurons is a candidate 
pathway that may be involved in the development of idiopathic PD. Dr Lynn Bedford  
Parkinson’s UK Senior Fellow, Nottingham University) presented her work to develop a 
genetic mouse model, by conditional deletion of the 26S proteasome in tyrosine 
hydroxylase positive neurons. Mice with this deletion show progressive neurodegeneration 
and the formation of Lewy-like inclusions containing α-synuclein, ubiquitinated proteins and 
mitochondria. However, when these mice were crossed with α-synuclein null mice, lack of 
α-synuclein had no effect on Lewy body formation suggesting that it may not be a key player 
in the process. 
 
The third session of the conference focussed on modelling PD in other animals and human 
cellular systems. Tilo Kunath (Parkinson’s UK Senior Fellow, Edinburgh University) presented 
research to generate induced pluripotent stem cell lines (iPSCs) from a patient with familial 
PD caused by triplication of the SNCA gene encoding α-synuclein. 
 
These iPSCs were differentiated into midbrain dopamine neurons and were shown to 
express double the levels of α-synuclein when compared to neurons derived from 
iPSCs generated from an unaffected family member. 
 
Animals such as zebra fish, Caenorhabditis elegans and Drosophila have been used to 
model neurodegenerative disease and offer advantages such as short life cycles, relatively 
straightforward gene manipulation, simplicity or easier visualisation of neuronal circuitry, 
and the potential to screen large numbers of animals for pathology or potential therapies. 
Oliver Bandmann (Sheffield University) described techniques by his group for transient 
knock down of the PD-related genes DJ-1, parkin and PINK1 by injecting antisense 
oligonucleotides into zebrafish embryos at the single cell stage.This morpholino strategy 
can generate stable lines that display key features of PD such as mitochondrial dysfunction 
and loss of dopaminergic neurons. 
 
Anton Gartner (Dundee University) presented research to generate PD models in C.elegans 
via α-synuclein gene mutation or using the 6-OHDA toxin to induce neurodegeneration. 
Using the 6-OHDA model to screen for neuroprotective genes, they have found that the 
membrane protein tetraspanin-17 may have a neuroprotective role for dopamine neurons 
depending on its specific expression level.  
 
Alex Whitworth (Sheffield University), presented data on Drosophila models of PD derived 
by mutating the genes: PINK1 and Rhomboid-7. Their research suggests that aberrant fusion 
of mitochondria stops their degradation and this may play a role in neuronal death in PD. 
The conference ended with an open discussion between the audience and a panel of 
experts: Paul Bolam, Oxford; Kieran Breen, Parkinson’s UK; Jose Obeso, Navarra; Richard 
Wade-Martins, Oxford; and Rosemary Fricker, Keele. Many issues were raised including: Is 
PD a syndrome rather than a single disease, and should we therefore be developing more 
complex models, or indeed using humans as models? Which models might be most useful 
for the Pharmaceutical industry, enabling better therapeutics to be developed for early 
PD? One of the problems discussed was the lack of biomarkers for models,particularly for 
in vivo imaging of rodents and primates to assess neuron degeneration and repair. The 
final conclusion? We should continue with both current and new avenues of research, as all 
models are good but none are yet sufficient. 
